Selected studies of children and adolescents with PMBCL
| Reference . | Study type . | Treatment . | N . | EFS, % . |
|---|---|---|---|---|
| 30 | Prospective, subgroup analysis pooled data from 3 studies | NHL-BFM 86, 90, 95 | 28 | 70 (5 y) |
| 31 | Prospective, subgroup analysis | FAB/LMB 96 | 42 | 66 (5 y) |
| 32 | Prospective phase 2 | DA-EPOCH-R | 40 | 69 (2 y) |
| 29 | Retrospective | DA-EPOCH-R | 38 | 81 (3 y) |
| Reference . | Study type . | Treatment . | N . | EFS, % . |
|---|---|---|---|---|
| 30 | Prospective, subgroup analysis pooled data from 3 studies | NHL-BFM 86, 90, 95 | 28 | 70 (5 y) |
| 31 | Prospective, subgroup analysis | FAB/LMB 96 | 42 | 66 (5 y) |
| 32 | Prospective phase 2 | DA-EPOCH-R | 40 | 69 (2 y) |
| 29 | Retrospective | DA-EPOCH-R | 38 | 81 (3 y) |
EFS, event-free survival.